Pleiotropic effects of bisphosphonates on osteosarcoma

Bone

Volumn 63, Issue , 2014, Pages 110-120

  Ohba, Tetsuro ^a,c   Cates, Justin M M ^a   Cole, Heather A ^a   Slosky, David A ^a   Haro, Hirotaka ^c   Ichikawa, Jiro ^c   Ando, Takashi ^c   Schwartz, Herbert S ^a   Schoenecker, Jonathan G ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Angiogenesis; Bisphosphonate; Endothelial cell; Osteosarcoma; VEGF A; VEGFR

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; MEVINOLIN; PITAVASTATIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEASIBILITY STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; OSTEOSARCOMA; PHARMACODYNAMICS; PLEIOTROPY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DIPHOSPHONATES; HUMANS; MICE; MICE, INBRED BALB C; OSTEOSARCOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896994450     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.03.005     Document Type: Article

References (43)

1. Goldsby R.E., Fan T.M., Villaluna D., Wagner L.M., Isakoff M.S., Meyer J., et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer 2013, 49:2384-2391.
2. Ward W.G., Mikaelian K., Dorey F., Mirra J.M., Sassoon A., Holmes E.C., et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994, 12:1849-1858.
3. Wunder J.S., Nielsen T.O., Maki R.G., O'Sullivan B., Alman B.A. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007, 8:513-524.
4. Noh K., Kim K.O., Patel N.R., Staples J.R., Minematsu H., Nair K., et al. Targeting inflammatory kinase as an adjuvant treatment for osteosarcomas. J Bone Joint Surg Am 2011, 93:723-732.
5. Van Poznak C.H., Temin S., Yee G.C., Janjan N.A., Barlow W.E., Biermann J.S., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
6. Ohba T., Cole H.A., Cates J.M., Slosky D.A., Haro H., Ando T., et al. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J Bone Miner Res 2014, (Jan 20, Electronic publication ahead of print). 10.1002/jbmr.2182.
7. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061.
8. Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002, 62:6538-6544.
9. Santini D., Vincenzi B., Galluzzo S., Battistoni F., Rocci L., Venditti O., et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007, 13:4482-4486.
10. Tang X., Zhang Q., Shi S., Yen Y., Li X., Zhang Y., et al. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 2010, 126:90-103.
11. Lee Y.H., Tokunaga T., Oshika Y., Suto R., Yanagisawa K., Tomisawa M., et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 1999, 35:1089-1093.
12. Yu X.W., Wu T.Y., Yi X., Ren W.P., Zhou Z.B., Sun Y.Q., et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol 2014, 35(1):155-160.
13. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
14. Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001, 19:1207-1225.
15. Rastogi S., Kumar R., Sankineani S.R., Marimuthu K., Rijal L., Prakash S., et al. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study. Int Orthop 2012, 36:2315-2321.
16. Yin D., Jia T., Gong W., Yu H., Wooley P.H., Mott M.P., et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol 2008, 33:253-259.
17. Sitohy B., Nagy J.A., Dvorak H.F. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012, 72:1909-1914.
18. Abdullah S.E., Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012, 118:3455-3467.
19. Luu H.H., Kang Q., Park J.K., Si W., Luo Q., Jiang W., et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005, 22:319-329.
20. Schmidt J., Strauss G.P., Schon A., Luz A., Murray A.B., Melchiori A., et al. Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation 1988, 39:151-160.
21. Ning Y., Chen S., Li X., Ma Y., Zhao F., Yin L. Cholesterol, LDL, and 25-hydroxycholesterol regulate expression of the steroidogenic acute regulatory protein in microvascular endothelial cell line (bEnd.3). Biochem Biophys Res Commun 2006, 342:1249-1256.
22. Ichikawa J., Cole H.A., Magnussen R.A., Mignemi N.A., Butler M., Holt G.E., et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma. Cancer 2012, 118:2494-2506.
23. Odri G.A., Dumoucel S., Picarda G., Battaglia S., Lamoureux F., Corradini N., et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res 2010, 70:7610-7619.
24. Daubine F., Le Gall C., Gasser J., Green J., Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99:322-330.
25. Cole H.A., Ichikawa J., Colvin D.C., O'Rear L., Schoenecker J.G. Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis. J Orthop Res 2011, 29:1957-1962.
26. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000, 18:261-271.
27. Weiss K.R., Cooper G.M., Jadlowiec J.A., McGough R.L., Huard J. VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res 2006, 450:111-117.
28. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
29. Hassan S.E., Bekarev M., Kim M.Y., Lin J., Piperdi S., Gorlick R., et al. Cell surface receptor expression patterns in osteosarcoma. Cancer 2012, 118:740-749.
30. Quan G.M., Choong P.F. Anti-angiogenic therapy for osteosarcoma. Cancer Metastasis Rev 2006, 25:707-713.
31. DuBois S., Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007, 109:813-819.
32. Gorlick R., Khanna C. Osteosarcoma. J Bone Miner Res 2010, 25:683-691.
33. Misso G., Porru M., Stoppacciaro A., Castellano M., De Cicco F., Leonetti C., et al. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther 2012, 13.
34. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
35. Yamada J., Tsuno N.H., Kitayama J., Tsuchiya T., Yoneyama S., Asakage M., et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009, 151:115-120.
36. Hamma-Kourbali Y., Di Benedetto M., Ledoux D., Oudar O., Leroux Y., Lecouvey M., et al. A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Commun 2003, 310:816-823.
37. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61:5736-5740.
38. Lee T.H., Seng S., Sekine M., Hinton C., Fu Y., Avraham H.K., et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007, 4:e186.
39. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
40. Savitskaya Y.A., Rico-Martinez G., Linares-Gonzalez L.M., Delgado-Cedillo E.A., Tellez-Gastelum R., Alfaro-Rodriguez A.B., et al. Serum tumor markers in pediatric osteosarcoma: a summary review. Clin Sarcoma Res 2012, 2:9.
41. Stresing V., Fournier P.G., Bellahcene A., Benzaid I., Monkkonen H., Colombel M., et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011, 48:259-266.
42. Scavelli C., Di Pietro G., Cirulli T., Coluccia M., Boccarelli A., Giannini T., et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007, 6:3256-3262.
43. Evans K.D., Oberbauer A.M. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J 2009, 3:83-88.